Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

Acta Haematologica
E Joanna Steer, Nicholas C P Cross

Abstract

Acquired reciprocal chromosomal translocations that involve chromosome bands 5q31-33 are associated with a significant minority of patients with BCR-ABL-negative chronic myeloid leukemias. The most common abnormality is the t(5;12)(q33;p13), which fuses the ETV6/TEL gene to the platelet-derived growth factor receptor-beta (PDGFRB), a receptor tyrosine kinase that maps to 5q33. PDGFRB is disrupted by other translocations and to date four additional partner genes (H4, HIP1, CEV14 and Rab5) have been reported. Clinically, most patients present with a myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic myelomonocytic leukemia and thus fall into the broader category of myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS). With the advent of targeted signal transduction therapy, patients with rearrangement of PDGFRB might be better classified as a distinct subgroup of MPD/MDS.

Citations

May 1, 2007·Current Hematologic Malignancy Reports·Sonja BurgstallerNicholas C P Cross
Sep 20, 2011·International Journal of Hematology·Jun YamanouchiMasaki Yasukawa
Mar 24, 2004·Leukemia Research·Geoffrey W Krystal
Oct 17, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Attilio OraziGail H Vance
Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Dec 17, 2002·Current Opinion in Hematology·Ema Anastasiadou, Juerg Schwaller
Jan 27, 2007·Current Opinion in Hematology·Ayalew Tefferi, James W Vardiman
Jul 5, 2005·Acta Haematologica·A Tefferi
Jun 26, 2007·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Donald Macdonald, Nicholas C Cross
Jun 26, 2007·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Attilio Orazi
Mar 6, 2009·Leukemia & Lymphoma·Peter Valent, Rotraud Wieser
Nov 19, 2010·Expert Review of Hematology·Judith NeukirchenUlrich Germing
Sep 1, 2007·Expert Opinion on Medical Diagnostics·Brijesh Arora, Ayalew Tefferi
May 3, 2014·Nigerian Medical Journal : Journal of the Nigeria Medical Association·O John-Olabode SarahxS Akanmu Alani
Jul 17, 2009·American Journal of Clinical Pathology·Juergen Thiele
Jul 9, 2003·British Journal of Haematology·Barbara J Bain
May 29, 2010·British Journal of Haematology·Peter L Greenberg
Jun 20, 2006·Best Practice & Research. Clinical Haematology·Ayalew Tefferi, Gary Gilliland
Aug 13, 2013·Case Reports in Hematology·Joel D Provenzano, J Phillip Kuebler
Apr 14, 2006·Mayo Clinic Proceedings·Ayalew TefferiAnimesh Pardanani
Mar 28, 2012·Seminars in Hematology·Pierre Noel
Dec 29, 2016·Blood·Andreas Reiter, Jason Gotlib
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David A ReardonHenry S Friedman
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dennis CornfieldGuoxian Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.